Literature DB >> 28249967

Atypical femoral fractures related to bisphosphonate treatment: issues and controversies related to their surgical management.

A Koh1, E Guerado2, P V Giannoudis3.   

Abstract

AIMS: Treatment guidelines for atypical femoral fractures associated with bisphosphonates have not been established. We conducted a systematic review of the treatment of atypical femoral fractures first, to evaluate the outcomes of surgical fixation of complete atypical fractures and secondly, to assess whether prophylactic surgery is necessary for incomplete atypical fractures.
MATERIALS AND METHODS: Case reports and series were identified from the PubMed database and were included if they described the treatment of atypical femoral fractures. In total, 77 publications met our inclusion criteria and 733 patients with 834 atypical complete or incomplete femoral fractures were identified.
RESULTS: For complete fractures, internal fixation was predominantly achieved by intramedullary nailing. The mean time to healing post-operatively was 7.3 months (2 to 31). Revision surgery for nonunion or implant failure was needed in 77 fractures (12.6%). A greater percentage of fractures treated with plate fixation (31.3%) required revision surgery than those treated with intramedullary nailing (12.9%) (p < 0.01). Non-operative treatment of incomplete fractures failed and surgery was eventually needed in nearly half of the patients (47%), whereas prophylactic surgery was successful and achieved a 97% rate of healing.
CONCLUSION: Intramedullary nailing is the first-line treatment for a complete fracture, although the risk of delayed healing and revision surgery seems to be higher than with a typical femoral fracture. Non-operative treatment does not appear to be a reliable way of treating an incomplete fracture: prophylactic intramedullary nailing should be considered if the patient is in intractable pain. Radiographs of the opposite side should be obtained routinely looking for an asymptomatic fracture. Bisphosphonates must be discontinued but ongoing metabolic management in the form of calcium and/or vitamin D supplements is advisable. Teriparatide therapy can be considered as an alternative treatment. Cite this article: Bone Joint J 2017;99-B:295-302. ©2017 The British Editorial Society of Bone & Joint Surgery.

Entities:  

Keywords:  Atypical femoral fracture; Bisphosphonate; Non-operative treatment; Prophylactic surgery; Surgical management

Mesh:

Substances:

Year:  2017        PMID: 28249967     DOI: 10.1302/0301-620X.99B3.BJJ-2016-0276.R2

Source DB:  PubMed          Journal:  Bone Joint J        ISSN: 2049-4394            Impact factor:   5.082


  29 in total

1.  A review of atypical subtrochanteric femoral fractures in Northern Ireland between 2010 and 2014.

Authors:  K J Donnelly; A Tucker; B Kerr; S McDonald; D S O'Longain; J D Acton
Journal:  Eur J Orthop Surg Traumatol       Date:  2017-12-22

2.  Surgical results of atypical femoral fractures in long-term bisphosphonate and glucocorticoid users - Relationship between fracture reduction and bone union.

Authors:  Tomofumi Nishino; Kojiro Hyodo; Yukei Matsumoto; Yohei Yanagisawa; Tomohiro Yoshizawa; Masashi Yamazaki
Journal:  J Orthop       Date:  2019-11-27

Review 3.  A proposal for an atypical femur fracture treatment and prevention clinical practice guideline.

Authors:  R Dell; D Greene
Journal:  Osteoporos Int       Date:  2018-04-19       Impact factor: 4.507

4.  Periprosthetic Fracture Resembling Atypical Femoral Fracture After Fixation With Retrograde Intramedullary Nail in Elderly Women: A Report of Two Cases.

Authors:  Yojiro Takahashi; Satoshi Hatashita; Yumetaka Shinden; Masayuki Ito; Yoichi Kaneuchi; Michiyuki Hakozaki; Shinichi Konno
Journal:  In Vivo       Date:  2021 May-Jun       Impact factor: 2.155

5.  [Atypical femoral fracture : Pitfalls in surgical treatment].

Authors:  J C Hopf; P M Rommens; P Drees; F Traub; D Wagner
Journal:  Unfallchirurg       Date:  2022-04-04       Impact factor: 1.000

6.  Atypical femur fractures associated with bisphosphonate therapy: post-operative outcomes.

Authors:  Benjamin Murphy; Sam L Francis; Isaac Rhee; Sina Babazadeh; James Stoney; Jarrad Stevens
Journal:  Eur J Orthop Surg Traumatol       Date:  2022-07-29

7.  Mechanism of Huangqi Sanxian Decoction Inhibiting Osteoclast Differentiation Based on Network Pharmacology.

Authors:  Jian-Xin Shi; Xiao-Qun Cai; Ze-Hao Zhao; Yu Deng; Zhi-Kun Zhou
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-08       Impact factor: 2.650

8.  Subtrochanteric and diaphyseal femoral fractures in hypophosphatasia-not atypical at all.

Authors:  F Genest; L Seefried
Journal:  Osteoporos Int       Date:  2018-05-17       Impact factor: 4.507

Review 9.  Surgical Treatment for Bisphosphonate-related Atypical Femoral Fracture: A Systematic Review.

Authors:  Adel Ebrahimpour; Mehrdad Sadighi; Amir Human Hoveidaei; Mohammadreza Chehrassan; Reza Minaei; Hamed Vahedi; Sm Javad Mortazavi
Journal:  Arch Bone Jt Surg       Date:  2021-05

10.  A Novel Surgical Method for Treating Symptomatic Incomplete Atypical Femoral Fracture using Percutaneous Elastic Intramedullary Nailing.

Authors:  Joon Hong Park; Yoon Je Cho; Young-Soo Chun; Kee Hyung Rhyu
Journal:  Geriatr Orthop Surg Rehabil       Date:  2021-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.